AC
NRXP icon

Armistice Capital’s NRX Pharmaceuticals NRXP Stock Holding History

Armistice Capital’s Portfolio NRXP Stock Details NRXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-563,600
Closed -$2.73M – 271
2023
Q2 		$2.73M Buy
+563,600
New +$3.39M 0.04% 134
2022
Q2 		– Sell
-625,978
Closed -$15.3M – 194
2022
Q1 		$15.3M Buy
+625,978
New +$20.4M 0.3% 63

Other funds holding NRXP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Armistice Capital's NRXP Position: Q3 2023 in Review

Armistice Capital sold out of NRX Pharmaceuticals (NRXP) in Q3 2023, closing a stake of 563,600 shares — an estimated $2.73M sold.

Armistice Capital first reported a position in NRXP in Q1 2022 and held it in 2 quarters. The position peaked at $15.3M in Q1 2022. 34 funds tracked by Wall St. Rank hold NRXP as of Q3 2023.

  • Armistice Capital reported no remaining NRX Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Armistice Capital sold 563,600 NRX Pharmaceuticals shares in Q3 2023, an estimated $2.73M.
  • Armistice Capital first reported a position in NRX Pharmaceuticals in Q1 2022 and held it in 2 quarters.
  • Armistice Capital's NRX Pharmaceuticals position peaked at $15.3M in Q1 2022.
  • 34 funds tracked by Wall St. Rank held NRX Pharmaceuticals as of Q3 2023.

Based on Armistice Capital's 13F filing for Q3 2023, filed 14 Nov 2023.